Tarsus Pharmaceuticals, Inc. TARS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s total equity?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total equity of $348.95M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s total equity changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s total equity increased by 1.9% year-over-year, from $342.46M to $348.95M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s total equity?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s total equity has grown at a 15.7% compound annual growth rate (CAGR), from $165.98M to $343.43M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.